These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 26060189)

  • 1. Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.
    Rouillon J; Poupiot J; Zocevic A; Amor F; Léger T; Garcia C; Camadro JM; Wong B; Pinilla R; Cosette J; Coenen-Stass AM; Mcclorey G; Roberts TC; Wood MJ; Servais L; Udd B; Voit T; Richard I; Svinartchouk F
    Hum Mol Genet; 2015 Sep; 24(17):4916-32. PubMed ID: 26060189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proteomics profiling of urine reveals specific titin fragments as biomarkers of Duchenne muscular dystrophy.
    Rouillon J; Zocevic A; Leger T; Garcia C; Camadro JM; Udd B; Wong B; Servais L; Voit T; Svinartchouk F
    Neuromuscul Disord; 2014 Jul; 24(7):563-73. PubMed ID: 24813925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of serum protein biomarkers in the mdx mouse model and cross-species comparison to Duchenne muscular dystrophy patients.
    Hathout Y; Marathi RL; Rayavarapu S; Zhang A; Brown KJ; Seol H; Gordish-Dressman H; Cirak S; Bello L; Nagaraju K; Partridge T; Hoffman EP; Takeda S; Mah JK; Henricson E; McDonald C
    Hum Mol Genet; 2014 Dec; 23(24):6458-69. PubMed ID: 25027324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of novel, therapy-responsive protein biomarkers in a mouse model of Duchenne muscular dystrophy by aptamer-based serum proteomics.
    Coenen-Stass AM; McClorey G; Manzano R; Betts CA; Blain A; Saleh AF; Gait MJ; Lochmüller H; Wood MJ; Roberts TC
    Sci Rep; 2015 Nov; 5():17014. PubMed ID: 26594036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic elevation in urinary amino terminal titin fragment excretion quantified by immunoassay in Duchenne muscular dystrophy patients and in dystrophin deficient rodents.
    Robertson AS; Majchrzak MJ; Smith CM; Gagnon RC; Devidze N; Banks GB; Little SC; Nabbie F; Bounous DI; DiPiero J; Jacobsen LK; Bristow LJ; Ahlijanian MK; Stimpson SA
    Neuromuscul Disord; 2017 Jul; 27(7):635-645. PubMed ID: 28554556
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is the normal content of sulfhydryl groups attributable to sparing from dystrophic pathology in dystrophin-deficient muscles?
    Niebrój-Dobosz I; Fidziańska A; Glinka Z; Hausmanowa-Petrusewicz I
    Folia Neuropathol; 2002; 40(3):143-50. PubMed ID: 12572920
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteomic profiling of x-linked muscular dystrophy.
    Lewis C; Carberry S; Ohlendieck K
    J Muscle Res Cell Motil; 2009 Dec; 30(7-8):267-9. PubMed ID: 20082121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biochemical characterization of patients with in-frame or out-of-frame DMD deletions pertinent to exon 44 or 45 skipping.
    Anthony K; Arechavala-Gomeza V; Ricotti V; Torelli S; Feng L; Janghra N; Tasca G; Guglieri M; Barresi R; Armaroli A; Ferlini A; Bushby K; Straub V; Ricci E; Sewry C; Morgan J; Muntoni F
    JAMA Neurol; 2014 Jan; 71(1):32-40. PubMed ID: 24217213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical Systemic Delivery of Adeno-Associated α-Sarcoglycan Gene Transfer for Limb-Girdle Muscular Dystrophy.
    Griffin DA; Pozsgai ER; Heller KN; Potter RA; Peterson EL; Rodino-Klapac LR
    Hum Gene Ther; 2021 Apr; 32(7-8):390-404. PubMed ID: 33349138
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
    Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
    Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three novel serum biomarkers, miR-1, miR-133a, and miR-206 for Limb-girdle muscular dystrophy, Facioscapulohumeral muscular dystrophy, and Becker muscular dystrophy.
    Matsuzaka Y; Kishi S; Aoki Y; Komaki H; Oya Y; Takeda S; Hashido K
    Environ Health Prev Med; 2014 Nov; 19(6):452-8. PubMed ID: 25150707
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wild-type mouse models to screen antisense oligonucleotides for exon-skipping efficacy in Duchenne muscular dystrophy.
    Cao L; Han G; Gu B; Yin H
    PLoS One; 2014; 9(11):e111079. PubMed ID: 25365558
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antisense Oligonucleotide Treatment in a Humanized Mouse Model of Duchenne Muscular Dystrophy and Highly Sensitive Detection of Dystrophin Using Western Blotting.
    Maruyama R; Yokota T
    Methods Mol Biol; 2021; 2224():203-214. PubMed ID: 33606217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular correction of Duchenne muscular dystrophy by splice modulation and gene editing.
    Hanson B; Wood MJA; Roberts TC
    RNA Biol; 2021 Jul; 18(7):1048-1062. PubMed ID: 33472516
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gene therapy for muscular dystrophy: lessons learned and path forward.
    Mendell JR; Rodino-Klapac L; Sahenk Z; Malik V; Kaspar BK; Walker CM; Clark KR
    Neurosci Lett; 2012 Oct; 527(2):90-9. PubMed ID: 22609847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Chronic, Maximal Phosphorodiamidate Morpholino Oligomer (PMO) Dosing on Muscle Function and Dystrophin Restoration in a Mouse Model of Duchenne Muscular Dystrophy.
    Benny Klimek ME; Vila MC; Edwards K; Boehler J; Novak J; Zhang A; Van der Meulen J; Tatum K; Quinn J; Fiorillo A; Burki U; Straub V; Lu QL; Hathout Y; van Den Anker J; Partridge TA; Morales M; Hoffman E; Nagaraju K
    J Neuromuscul Dis; 2021; 8(s2):S369-S381. PubMed ID: 34569970
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of ultrasonography for non-invasive assessment of diaphragm function in muscular dystrophy.
    Whitehead NP; Bible KL; Kim MJ; Odom GL; Adams ME; Froehner SC
    J Physiol; 2016 Dec; 594(24):7215-7227. PubMed ID: 27570057
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Enhanced expression of the alpha 7 beta 1 integrin reduces muscular dystrophy and restores viability in dystrophic mice.
    Burkin DJ; Wallace GQ; Nicol KJ; Kaufman DJ; Kaufman SJ
    J Cell Biol; 2001 Mar; 152(6):1207-18. PubMed ID: 11257121
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased plasma lipid levels exacerbate muscle pathology in the mdx mouse model of Duchenne muscular dystrophy.
    Milad N; White Z; Tehrani AY; Sellers S; Rossi FMV; Bernatchez P
    Skelet Muscle; 2017 Sep; 7(1):19. PubMed ID: 28899419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dantrolene enhances antisense-mediated exon skipping in human and mouse models of Duchenne muscular dystrophy.
    Kendall GC; Mokhonova EI; Moran M; Sejbuk NE; Wang DW; Silva O; Wang RT; Martinez L; Lu QL; Damoiseaux R; Spencer MJ; Nelson SF; Miceli MC
    Sci Transl Med; 2012 Dec; 4(164):164ra160. PubMed ID: 23241744
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.